Argenica Therapeutics Banner Image

Argenica Therapeutics

  • Ticker AGN
    Exchange ASX More
  • Industry Biotechnology More
  • Sector Healthcare More
Argenica Therapeutics Logo Image
  • 1-10 Employees
  • Based in Nedlands, Australia
Argenica is developing and seeking to commercialise a “best in class” neuroprotective cationic arginine- rich peptide therapy to improve outcomes in stroke patients. Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. MoreoverMore, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity.
Argenica Therapeutics

Most Recent Annual Report

Argenica Therapeutics
MOST RECENT 2021 Annual Report